Consuelo Buttigliero

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3773165/publications.pdf

Version: 2024-02-01

60 papers	1,395 citations	361413 20 h-index	361022 35 g-index
60 all docs	60 docs citations	60 times ranked	2550 citing authors

#	Article	IF	Citations
1	Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. European Urology, 2022, 81, 274-282.	1.9	55
2	Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Minerva Urology and Nephrology, 2022, 73, .	2.5	4
3	New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. Cells, 2022, 11, 357.	4.1	16
4	Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?. Minerva Urology and Nephrology, 2022, 73, 870-872.	2.5	3
5	Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study. Minerva Urology and Nephrology, 2022, , .	2.5	2
6	First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial.. Journal of Clinical Oncology, 2022, 40, 439-439.	1.6	2
7	Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. Cells, 2022, 11, 803.	4.1	19
8	Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. Tumori, 2022, , 030089162210771.	1.1	1
9	New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?. Critical Reviews in Oncology/Hematology, 2022, 174, 103682.	4.4	5
10	Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?. Cells, 2022, 11, 1614.	4.1	1
11	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. Critical Reviews in Oncology/Hematology, 2021, 157, 103185.	4.4	41
12	Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer and Prostatic Diseases, 2021, 24, 812-825.	3.9	5
13	Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.. Journal of Clinical Oncology, 2021, 39, 5047-5047.	1.6	1
14	Programmed death ligand-1 (PD-L1) expression in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in NIVES study.. Journal of Clinical Oncology, 2021, 39, 4558-4558.	1.6	1
15	Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. Endocrine-Related Cancer, 2021, 28, R207-R216.	3.1	14
16	Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. European Journal of Cancer, 2021, 155, 127-135.	2.8	3
17	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 1250-1264.	10.7	159
18	Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report. Tumori, 2021, 107, NP149-NP154.	1.1	4

#	Article	IF	Citations
19	The prognostic value of pain in castration-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 654-660.	3.9	7
20	Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review. Cancers, 2020, 12, 2568.	3.7	8
21	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. Critical Reviews in Oncology/Hematology, 2020, 152, 102994.	4.4	13
22	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) â€“ updated interim analysis (IA).. Journal of Clinical Oncology, 2020, 38, 5566-5566.	1.6	15
23	TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)â€”First interim analysis (IA).. Journal of Clinical Oncology, 2020, 38, 119-119.	1.6	31
24	Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study.. Journal of Clinical Oncology, 2020, 38, 613-613.	1.6	25
25	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. , 2020, 3, 726-741.		6
26	Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 737-745.	3.9	6
27	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. Journal of Clinical Oncology, 2020, 38, TPS762-TPS762.	1.6	1
28	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.. Journal of Clinical Oncology, 2020, 38, TPS596-TPS596.	1.6	0
29	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. Clinical Genitourinary Cancer, 2019, 17, 332-347.e2.	1.9	9
30	Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents. Endocrine, 2019, 64, 724-726.	2.3	5
31	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. Future Oncology, 2019, 15, 1115-1123.	2.4	9
32	Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Nonâ€Small Cell Lung Cancer. Oncologist, 2019, 24, e251-e259.	3.7	11
33	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Cancer Treatment Reviews, 2019, 74, 35-42.	7.7	30
34	Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.. Journal of Clinical Oncology, 2019, 37, 219-219.	1.6	3
35	Prostate cancer management at an Italian tertiary referral center: does multidisciplinary team meeting influence diagnostic and therapeutic decision-making process? A snapshot of the everyday clinical practice. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 576-582.	3.9	16
36	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Endocrine-Related Cancer, 2018, 25, R1-R9.	3.1	13

#	Article	IF	Citations
37	Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 124-133.	1.1	52
38	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. OncoTargets and Therapy, 2018, Volume 11, 7353-7368.	2.0	58
39	Hormonal treatment and quality of life of prostate cancer patients: new evidence. Minerva Urology and Nephrology, 2018, 70, 144-151.	2.5	25
40	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treatment Reviews, 2018, 69, 215-223.	7.7	19
41	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 129, 124-132.	4.4	18
42	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treatment Reviews, 2018, 70, 67-74.	7.7	41
43	Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review. Clinical Genitourinary Cancer, 2018, 16, e1087-e1090.	1.9	4
44	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. Clinical Genitourinary Cancer, 2018, 16, 318-324.	1.9	4
45	Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Acta OncolÃ³gica, 2017, 56, 555-562.	1.8	24
46	Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. Cancer Treatment Reviews, 2017, 54, 1-9.	7.7	44
47	Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma. Endocrine Pathology, 2017, 28, 95-102.	9.0	15
48	Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias?. Journal of Clinical Oncology, 2017, 35, 1264-1264.	1.6	1
49	Zoledronic Acid Dosing Interval for Metastatic Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1477.	7.4	0
50	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. BioMed Research International, 2017, 2017, 1-13.	1.9	10
51	Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. Translational Lung Cancer Research, 2016, 5, 610-627.	2.8	13
52	Androgen deprivation modulates gene expression profile along prostate cancer progression. Human Pathology, 2016, 56, 81-88.	2.0	20
53	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treatment Reviews, 2016, 44, 61-73.	7.7	56
54	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 69, 563-573.	1.9	101

#	Article	IF	Citations
55	Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. Oncotarget, 2016, 7, 14394-14404.	1.8	23
56	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. European Urology, 2015, 68, 147-153.	1.9	73
57	The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome. Endocrine, 2015, 50, 223-230.	2.3	18
58	Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. Human Pathology, 2015, 46, 1799-1807.	2.0	44
59	Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treatment Reviews, 2015, 41, 884-892.	7.7	141
60	Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget, 2015, 6, 12520-12528.	1.8	47